Drug Profile
OMS 405
Alternative Names: OMS 403; OMS405Latest Information Update: 23 Feb 2023
Price :
$50
*
At a glance
- Originator University of Camerino
- Developer New York State Psychiatric Institute; Omeros Corporation
- Class Drug withdrawal therapies; Small molecules; Smoking cessation therapies
- Mechanism of Action Peroxisome proliferator-activated receptor gamma agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Opioid-related disorders; Smoking withdrawal
- Preclinical Alcoholism
Most Recent Events
- 23 Feb 2023 Preclinical development for Alcoholism is still ongoing in USA (Omeros Corporation pipeline, February 2023)
- 15 Feb 2023 Omeros Corporation has a multiple patent protection for OMS 405 in USA and world-wide before February 2023
- 15 Feb 2023 Omeros Corporation has a multiple pending patents for OMS 405 in USA and world-wide before February 2023